Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New baby formula aims to soothe milk allergy symptoms

NCT ID NCT07484035

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new extensively hydrolyzed formula for infants aged 0-5 months with mild-to-moderate cow's milk protein allergy (CMPA). The formula is designed to relieve symptoms like skin rashes, stomach issues, and breathing problems. Over 28 days, researchers will compare the new formula to an existing one to see if it works just as well and is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 124 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 to 5 months

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects must meet all of the following criteria to be eligible for participation: * Born at 37-42 weeks gestation with birth weight 2500-4000 g * Aged 0 to 5 months at enrollment * Diagnosed with mild-to-moderate CMPA by a physician based on the Nowak-Wegrzyn (2019) diagnostic criteria, meeting any of the following prior to enrollment: (a) Typical allergic symptoms + sensitization markers * Symptoms: Clear allergic reactions (e.g., urticaria, vomiting, dyspnea) following exposure to cow's milk or dairy products * Evidence of sensitization (any one of the following): * Serum cow's milk-specific IgE \>0.7 kIU/L * Serum cow's milk-specific IgE \>0.35 kUA/L * Positive skin prick test (wheal diameter ≥5 mm) (b) High-threshold serum specific IgE * Infants aged \<1 year: Cow's milk-specific IgE ≥5 kIU/L (c) Strongly positive SPT * SPT wheal diameter ≥10 mm (regardless of age) (d) Positive oral food challenge under medical supervision * Dietary elimination for at least 2 weeks, followed by OFC provoking immediate allergic reactions (e) Physician-confirmed diagnosis * Physician-confirmed diagnosis of CMPA supported by medical records dated within 2 weeks * Written informed consent voluntarily signed by at least one parent or legal guardian * Parents or legal guardians able to understand the informed consent form and other study documents, and willing and able to comply with study requirements * Parents or legal guardians agree not to enroll the infant in any other clinical studies during the trial period Exclusion Criteria: Subjects meeting any of the following criteria are not eligible for participation: * Recent onset of allergic symptoms due to causes other than cow's milk protein (including other food allergens, inhalant allergies, contact allergies, drug allergies, insect bite allergies, etc.) * Use of any extensively hydrolyzed formula (eHF) or amino acid formula (AAF) for the treatment of cow's milk protein allergy within 1 month prior to enrollment * Known intolerance to ingredients in the study formula (e.g., lactose intolerance) * Severe cow's milk protein allergy requiring treatment with amino acid formula (AAF) * Presence of severe congenital diseases or malformations, major organ dysfunction, genetic or metabolic disorders, or infectious diseases of the gastrointestinal tract or other sites * Growth retardation due to causes other than cow's milk protein allergy, or other significant medical conditions that, in the opinion of the investigator, may affect growth and/or development * Need for specialized diets or feeding methods (e.g., amino acid formula, metabolic disorder formula, or tube feeding) * Complementary foods already introduced * Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study * Concurrent participation in another clinical study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cow's milk protein allergy (CMPA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Heiner syndrome Milk Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Jingdu Children's Hospital

    Beijing, Beijing Municipality, 102208, China

  • Foshan Maternal and Child Health Hospital

    Foshan, Guangdong, 528000, China

  • Sichuan Jinxin Xinan Women's and Children's Hospital

    Chengdu, Sichuan, 610000, China

  • Wuxi Maternal and Child Health Hospital

    Wuxi, Jiangsu, 214000, China

  • Xiangtan County Maternal and Child Health Hospital

    Xiangtan, Hunan, 411200, China

  • Zhuhai Maternal and Child Health Hospital

    Zhuhai, Guangdong, 519000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.